These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24954039)

  • 1. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
    Young DL; Halstead LA
    J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.
    Kendall KA; Leonard RJ
    J Voice; 2011 Jan; 25(1):114-9. PubMed ID: 20137891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
    Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
    J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
    Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
    J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.
    Simpson CB; Lee CT; Hatcher JL; Michalek J
    Laryngoscope; 2016 Jan; 126(1):118-21. PubMed ID: 26467807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
    Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current practices in the management of adductor spasmodic dysphonia.
    Eskander A; Fung K; McBride S; Hogikyan N
    J Otolaryngol Head Neck Surg; 2010 Oct; 39(5):622-30. PubMed ID: 20828529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.
    van Esch BF; Wegner I; Stegeman I; Grolman W
    Otolaryngol Head Neck Surg; 2017 Feb; 156(2):238-254. PubMed ID: 27803079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
    Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
    J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Onabotulinum Toxin A Treatment for Adductor Spasmodic Dysphonia and Laryngeal Tremor.
    Patel PN; Kabagambe EK; Starkweather JC; Keller M; Gamsarian V; Lee J; Kulkarni V; Garrett CG; Francis DO
    JAMA Otolaryngol Head Neck Surg; 2018 Apr; 144(4):293-299. PubMed ID: 29423509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
    Bradley JP; Barrow EM; Hapner ER; Klein AM; Johns MM
    J Voice; 2017 May; 31(3):363-365. PubMed ID: 27839987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spasmodic dysphonia: a seven-year audit of dose titration and demographics in the Indian population.
    Nerurkar NK; Banu TP
    J Laryngol Otol; 2014 Jul; 128(7):649-53. PubMed ID: 24999662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abductor paralysis after botox injection for adductor spasmodic dysphonia.
    Venkatesan NN; Johns MM; Hapner ER; DelGaudio JM
    Laryngoscope; 2010 Jun; 120(6):1177-80. PubMed ID: 20513036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience.
    Tang CG; Novakovic D; Mor N; Blitzer A
    Laryngoscope; 2016 Mar; 126(3):678-81. PubMed ID: 26308153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.
    Mendelsohn AH; Berke GS
    Ann Otol Rhinol Laryngol; 2012 Apr; 121(4):231-8. PubMed ID: 22606926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
    Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
    J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
    Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
    Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort.
    Dharia I; Bielamowicz S
    Laryngoscope; 2020 Nov; 130(11):2659-2662. PubMed ID: 31837152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia.
    Lerner MZ; Lerner BA; Patel AA; Blitzer A
    Laryngoscope; 2017 May; 127(5):1131-1134. PubMed ID: 27633917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.